Chiesi Farmaceutici S.p.a.

Laboratorios Salvat, S.a.

Natividad Toledo Mesa

Juan Lorenzo Catena Ruiz

Carmen Lagunas Arnal

Carles Farrerons Gallemi

Carolina Salcedo Roca

Andrés Fernandez Garcia

Ignacio José Miquel Bono

Dolors Balsa Lopez

Anna Fernandez Serrat

Carmen Serra Comas

Amadeu Llebaria Soldevila

Diego Haro Bautista

Pedro Marrero Gonzalez

Arnau Cordomi Montoya

Carbamate of general formula (I), wherein R1, R2, and R3 are H, OH, NO, SH, CN, F, Cl, Br, I, COOH, CONH, (C-C)-alkoxycarbonyl, (C-C)-alkylsulfanyl, (C-C)-alkylsulfinyl, (C-C)-alkylsulfonyl, (C-C)-alkoxyl optionally substituted with one or several F, and (C-C)-alkyl optionally substituted with one or several F or OH; R4 is cycloalkyl, phenyl, heteroaryl or a bicyclic ring system; R5 is cycloalkyl, (C-C)-alkyl, a substituted (C-C)-alkyl; and Xis a physiologically acceptable anion. Carbamate (I) is selective Mreceptor antagonists versus Mreceptor and may be used for the treatment of urinary incontinence (particularly, the one caused by overactive bladder), irritable bowel syndrome, and respiratory disorders (particularly, chronic obstructive pulmonary disease, chronic bronchitis, asthma, emphysema, and rhinitis), as well as in ophthalmic interventions. 

1-alkyl-1-azoniabicyclo' 2.2.2 octane carbamate derivatives and their use as muscarinic receptor antagonists

Growing community of inventors

Vilanova del Vallès, Spain

Natividad Toledo Mesa